Day

August 6, 2018
Chimeric antigen receptor T-cell therapy, also known as CAR T-cell therapy, is approved for two indications — relapsed or refractory large B-cell lymphoma and B-cell acute lymphoblastic leukemia — and is currently being investigated for more cancer types. CAR T-cell therapy comprises T cells collected from a patient that are then engineered to recognize an...
Continue Reading

Floor 7, 90 The Terrace
Wellington Central
New Zealand